scholarly journals Comparison of WHO and RECIST Criteria for Evaluation of Clinical Response to Chemotherapy in Patients with Advanced Breast Cancer

2012 ◽  
Vol 13 (7) ◽  
pp. 3213-3218 ◽  
Author(s):  
Samina Khokher ◽  
Muhammad Usman Qureshi ◽  
Naseer Ahmad Chaudhry
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Clinical Response ◽  
Advanced Breast ◽  
Response To Chemotherapy ◽  
Criteria For Evaluation

scholarly journals A Phase II Study of Sequential Treatment with Anthracycline and Taxane Followed by Eribulin in Patients with HER2-negative, Locally Advanced Breast Cancer (JBCRG-17)

2021 ◽  
Author(s):  
Ippei Fukada ◽  
Yoshinori Ito ◽  
Naoto Kondo ◽  
Shoichiro Ohtani ◽  
Masaya Hattori ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Clinical Response ◽  
Phase Ii ◽  
Response Rate ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Advanced Breast ◽  
Clinical Response Rate ◽  
Sequential Administration

Abstract PurposeThe sequence of taxanes (T) followed by anthracyclines (A) as neoadjuvant chemotherapy (NAC) has been the standard of care for almost 20 years for locally advanced breast cancer (LABC). Sequential administration of eribulin (E) following A/T could provide a greater response rate for women with LABC.MethodsIn this single-arm, multicenter, Phase II prospective study, the patients received 4 cycles of the FEC regimen and 4 cycles of taxane. After the A/T-regimen, 4 cycles of E were administered followed by surgical resection. The primary endpoint was the clinical response rate. Eligible patients were women aged 20 years or older, with histologically confirmed invasive breast cancer, clinical Stage IIIA (T2-3 and N2 only), Stage IIIB, and Stage IIIC, HER2-negative.ResultsA preplanned interim analysis aimed to validate the trial assumptions was conducted after treatment of 20 patients and demonstrated that clinical progressive disease (cPD) rates in the E phase were significantly higher (30%) than assumed. Therefore, the Independent Data Monitoring Committee recommended stopping the study. Finally, 53 patients were enrolled, and 26 patients received the A/T/E-regimen. The overall observed clinical response rate (RR) was 73% (19/26); RRs were 77% (20/26) in the AT phase and 23% (6/26) in the E phase. Thirty percent (8/26) of patients had PD in the E phase, 6 of whom had achieved cCR/PR in the AT phase. Reported grade >3 AEs related to E were neutropenia (42%), white blood cell count decrease (27%), febrile neutropenia (7.6%), weight gain (3.8%), and weight loss (3.8%)ConclusionSequential administration of eribulin after the A/T-regimen provided no additional effect for LABC patients. Future research should continue to focus on identifying specific molecular biomarkers that can improve response rates.

scholarly journals Relationship of Polymorphisms of Glutathione S-Transferase GSTT1 and GSTM1 With the Response to Chemotherapy In Mexican Women with Advanced Breast Cancer

2011 ◽  
Vol 02 (03) ◽  
pp. 354-361 ◽  
Author(s):  
Odeth Soto-Quintana ◽  
Paula Cabrera-Galeana ◽  
Gabriel Téllez-Trevilla ◽  
José Luis Barrera-Franco ◽  
Alejandro Juárez-Ramiro ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
Mexican Women ◽  
Glutathione S Transferase ◽  
Response To Chemotherapy ◽  
Relationship Of

Thymidine kinase as a predictor of response to chemotherapy in advanced breast cancer

1984 ◽  
Vol 4 (3) ◽  
pp. 221-225 ◽  
Author(s):  
Hui-Jian Zhang ◽  
B. J. Kennedy ◽  
David T. Kiang
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Thymidine Kinase ◽  
Advanced Breast ◽  
Response To Chemotherapy

Estrogen receptor status and response to chemotherapy in advanced breast cancer: The tufts-shattuck-pondville experience

Cancer ◽  
1980 ◽  
Vol 46 (S12) ◽  
pp. 2919-2921 ◽  
Author(s):  
Charles Rosenbaum ◽  
Thomas A. Marsland ◽  
Leo L. Stolbach ◽  
Shanthi Raam ◽  
Joseph L. Cohen
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Advanced Breast Cancer ◽  
Estrogen Receptor Status ◽  
Advanced Breast ◽  
Receptor Status ◽  
Response To Chemotherapy

Clinical response of patients with advanced breast cancer treated with dendritic cell vaccine with and without thymalfasin

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 2593-2593
Author(s):  
G. A. Moviglia ◽  
C. Gaeta ◽  
V. Gabriela ◽  
P. Farina ◽  
H. Costanzo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dendritic Cell ◽  
Advanced Breast Cancer ◽  
Clinical Response ◽  
Dendritic Cell Vaccine ◽  
Advanced Breast ◽  
Cell Vaccine
Sign in / Sign up

Export Citation Format

Share Document